Gland Pharma Limited is an injectable-focused pharmaceutical company set up in Hyderabad in 1978 by P.V.N. Raju. It makes small-molecule generic injectables across sterile injectables, oncology and ophthalmic segments, and sells into more than 60 countries including the United States, Europe, Canada, Australia and India. The business runs largely on a B2B and CDMO model, supplying and co-developing complex injectables for global pharmaceutical partners.
The company runs seven manufacturing sites in India: four for finished formulations and three for active pharmaceutical ingredients. These include the Dundigal formulations and R&D campus in Hyderabad, penems and MPSF units at Pashamylaram, an oncology plant in the Visakhapatnam SEZ, and an API plant at Jawaharlal Nehru Pharma City, Visakhapatnam. Shanghai Fosun Pharma became the majority promoter, and Gland Pharma listed on the NSE and BSE in 2020.
FY26 was a record year. Consolidated revenue rose 14% to INR 64,307 Mn with an adjusted EBITDA margin of about 26%, and adjusted profit after tax climbed roughly 50%. CDMO work drove much of the growth, contributing 46% of Q4 revenue, and the European subsidiary Cenexi grew 25%. The company filed 24 ANDAs and secured 28 approvals in FY26, taking cumulative US ANDA filings to 388, and has committed INR 2,000 crore of capital expenditure over five years.